Amneal Pharmaceuticals/$AMRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
- Ticker
- $AMRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 8,700
- Headquarters
- Bridgewater, United States
- Website
- www.amneal.com
AMRX Metrics
BasicAdvanced
$7.5B
44.74
$0.48
1.24
-
Price and volume
Market cap
$7.5B
Beta
1.24
52-week high
$21.68
52-week low
$10.06
Average daily volume
3.8M
Financial strength
Current ratio
2.205
Quick ratio
1.375
Long term debt to equity
22.827
Total debt to equity
23.865
Interest coverage (TTM)
2.18%
Profitability
EBITDA (TTM)
694.81
Gross margin (TTM)
39.81%
Net profit margin (TTM)
5.05%
Operating margin (TTM)
15.88%
Effective tax rate (TTM)
-7.03%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.60%
Return on equity (TTM)
613.02%
Valuation
Price to earnings (TTM)
44.735
Price to revenue (TTM)
2.18
Price to book
207.99
Price to tangible book (TTM)
-5.98
Price to free cash flow (TTM)
-552.261
Free cash flow yield (TTM)
-0.18%
Free cash flow per share (TTM)
-0.039
Growth
Revenue change (TTM)
9.28%
Earnings per share change (TTM)
4,332.00%
3-year revenue growth (CAGR)
10.48%
3-year earnings per share growth (CAGR)
229.37%
What the Analysts think about AMRX
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
Analyst projections of the future price of Amneal Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue rose 10% and adjusted EPS rose 20% year on year, prompting Amneal to raise its 2026 revenue and EBITDA guidance. That points to solid near-term momentum across its businesses. (Amneal Pharmaceuticals)
Amneal launched its FDA-approved lanreotide injection in September, targeting a market where the reference product had nearly $1bn in US sales over the prior 12 months. This adds a potentially sizeable product to its complex injectables portfolio. (Amneal Pharmaceuticals)
The completed Kashiv acquisition gives Amneal in-house biosimilar research, manufacturing and commercial capabilities. That platform could provide a new long-term growth stream as more biologic medicines lose exclusivity. (Amneal Pharmaceuticals)
The Kashiv deal adds to an already sizeable debt burden: Amneal reported about $2.68bn of total debt at June-end and planned a further $350m term loan to fund part of the acquisition. That could make the company’s deleveraging target harder to reach. (StockTitan, Amneal Pharmaceuticals)
Operating cash flow was negative by about $48m in the first half of 2026, while Amneal raised its 2026 capital expenditure outlook from about $110m to $150m. That combination leaves less near-term cash flexibility. (StockTitan, The Motley Fool)
Manufacturing execution has faced setbacks: flooding at an Indian facility was expected to reduce 2026 results by about $20m, and Amneal recalled 5,694 exenatide pens after a delivery-system defect could leave them without medicine. These events highlight supply and product-quality risks. (The Motley Fool, The Economic Times)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
AMRX Financial Performance
Revenues and expenses
AMRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AMRX
Fund name | Fund size | $AMRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.47% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.47% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.22% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.22% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.